We can make mRNA from 100bp to 20kb in length. For oligo shorter than 100bp, our oligo synthesis team can take it under chemical syntehsis.
Celebrate RNA Month this August: 30% off mRNA & LNP
—use code RNAMONTH30 (US only)
Fast Delivery for Speedy Discovery
Industry-leading 3-week turnaround time from Gene-to-mRNA for global customers
Cutting Edge Innovations
Innovations in mRNA, circular RNA, self-amplifying RNA, mRNA vector design, etc. with patented technologies for optimized RNA performance
Integrated Solutions
From gene to mRNA to LNP formulation
GenScript’s solution to IVT mRNA manufacturing streamlines your workflow from gene synthesis to mRNA production. Our IVT mRNAs are optimized with our proprietary production platform, ensuring the quality and expression efficiency of your mRNA.
Codon/UTR Optimization
Gene Synthesis
Cloning/Plasmid Synthesis
mRNA Synthesis
Lipid Nanoparticles Delivery
Try our catalog mRNA expressing reporter genes, Cas protein, or SB-100 transposase, all delivered in just 5 days!
QC | Item | Test Method | Specification | RUO Default |
RUO Upgrade |
Preclinical Default |
Preclinical Upgrade |
---|---|---|---|---|---|---|---|
Identification | Appearance | Visual Inspect | Clear and free of foreign particles | ||||
RNA Length | Capillary Electrophoresis | Target ± 30% | |||||
RNA Length | Agarose Gel Electrophoresis | Expected size band detected | |||||
Poly A Length | Enzyme digestion to LC-MS | Target ± 5% | |||||
RNA Content | UV Absorbance | Target ± 5% | |||||
PH | pH meter | Target ± 0.5 | |||||
Buffer Specification | Client Spec | N/A | |||||
Sequencing | Sanger Sequencing | >98% Alignment | |||||
Sequencing | NGS by Illumina | Q20 Ratio > 95% | Upon Request | ||||
Purity | A 260/280 Ratio | UV Spec | 1.70 ~ 2.30 | ||||
Capping Efficiency | LC-MS | ≥ 90% | |||||
Size based purity | Capillary Electrophoresis | ≥75% | |||||
Impurity | Total protein residue | Nano Orange Assay | ≤ 1% | ||||
Plasmid DNA Residue | qPCR | ≤ 0.05% | |||||
dsRNA | Slot-blot | ≤ 0.1% | |||||
Aggregate mRNA | SEC-HPLC | < 20% | Upon Request | ||||
Fragment mRNA | RP-HPLC | <25% | Upon Request | ||||
Safety | Endotoxin | Semiquantitative | < 10EU/mg | ||||
Endotoxin | Quantitative | < 10EU/mg | |||||
Bioburden | Direct inoculation | No Growth after 72 hrs |
Note: Additional QC and characterizations are offered with an extra charge upon request.
Linear mRNA | Self-Amplifying RNA | Circular RNA | |||||
![]() |
![]() |
![]() |
|||||
Structure | Linear; Open 5’ and 3’ end mRNA exonuclease degradation |
Linear; Open 5’ and 3’ end mRNA exonuclease degradation |
Close loop; No free 5’ 3’ end Eliminating mRNA exonuclease degradation |
||||
Ribosome recruiting | 5’ Cap: Initiates translation & stabilizes mRNA |
5’ Cap: Initiates translation & stabilizes mRNA |
Internal Ribosome Entry Site (IRES) : Initiates translation |
||||
ORF |
|
|
|
||||
UTR | Regulatory elements in the 5’ and 3’-UTR stabilize mRNA and increase translation initiation | Replicon for further self-replication of the mRNA | Include IRES + PIE + other elements | ||||
PolyA tail | Stabilizes RNA molecule & Prevents degradation | Stabilizes RNA molecule & Prevents degradation | Not required | ||||
Protein Expression | +++ Strong | +++++ Strongest | ++++ Stronger | ||||
Expression half-life | +++ Shorter | +++++ Longest | ++++ Longer | ||||
Immunogenicity | ++++ Low | ++ High | +++ Medium | ||||
Dosage requirement | ++ High | +++++ Lowest | +++ Medium | ||||
Novelty | +++ Traditional | ++++ Novel | +++++ Novel | ||||
Chun-YuChen
Seattle Children's Hospital
I purchased mRNA from different companies and found that GenScript's mRNA showed higher expression (almost 2 fold) and much more cost effective!!
François Iv
Evotec (France) SAS
GenScript mRNA has helped us make a rapid progress in developing novel vaccine projects. GenScript's service is faithful and timely provided, saving me lots of time to focus on research. This is why I have been using GenScript services for over 20 years.
Dr. Sang-Moo Kang
institute1 for Biomedical Sciences at Georgia State University
We have utilized GenScript's gene and mRNA synthesis service for our research projects, and the outcomes have been exceptional. The product quality, timely delivery, and technical support have consistently surpassed our expectations.
Questions On Storage And Usage Guidelines_mRNA, saRNA and LNP
CRISPR Knock-in Protocol for HEK 293T/293 cells with Thermo Fisher Neon® Transfection System
Free DownloadmRNA Case Study Report
Case studies showing high expression efficiency of GenScript’s mRNA for expressing SB transposase, GFP, Luciferase, eSpCas9, and more.
Free DownloadCritical Consideration in Sourcing mRNA_Whitepaper
This whitepaper provides valuable insights into the essential factors that vaccine and therapy developers should consider when exploring mRNA solutions
Free DownloadAdvancements in mRNA manufacturing_eBook
Get GenScript’s free application eBook on therapeutics development with mRNA manufacturing solutions
Free DownloadmRNA Therapy Modalities_Infographic
Learn about key structural features and functions of IVT mRNA and LNP, therapeutic modalities beyond prophylactic vaccines, mRNA candidates progressing through clinical trials.
Free DownloadmRNA Parts_Infographic
Learn about the main structural components of mRNA, the functional roles of each part, what constitutes high-quality IVT mRNA and more.
Free DownloadWe can make mRNA from 100bp to 20kb in length. For oligo shorter than 100bp, our oligo synthesis team can take it under chemical syntehsis.
For RUO grade mRNA, we use silica membrane or LiCl precipitation method for purification. It is suitable for in vitro and invivo proof of concept studies.
For preclinical grade, we use HPLC based Oligo dT purification for improving RNA purity. Preclinical grade can be considered for long mRNA constructs >5kb or when high RNA purity (less fragment RNA ) is required for the project.
We can provide cGMP mRNA through our sister company ProBio. Please contact our technical support team.
Yes. We guarantee specific amounts of mRNA be delivered.
We ship mRNA at concentration of 0.5 ~2mg/mL by default. We can adjust concentration to a specific value <4mg /mL per customer's request at extra cost.
We offer 3 options of buffer: 1mM sodium citrate pH 6.5, TE pH7, and RNase-Free H2O. 1mM sodium citrate is our default option for better mRNA stability.
mRNA should be stable for at least 1 year if stored properly at -80°C upon receival and avoiding repeated freezing and thawing cycles, however mRNA stability varies depending on the length of mRNA. We have tested mRNA with stable results up to 3 freeze/thaw cycles. We recommend storing at -80°C for long time storage and -20°C for short term storage.
For RUO grade mRNA, we use silica membrane or LiCl precipitation method for purification.
For preclinical grade, we use HPLC-based Oligo dT purification for improving RNA purity.
In addition, we offer optional dephosphorylation to further reduce triphosphate RNA species in the final product to reduce its immunogenicity, and optional dsRNA removal HPLC purification to provide higher quality mRNA if low dsRNA residue is required.
Cellulose based HPLC method.
For size-based purity, we run the mRNA sample on bioanalyzer, then calculate the ratio of the main peak (target size +-15%) over the total AUC.
We recommend customers dephosphorylation as reducing the triphosphate-RNA species in mRNA by dephosphorylation could reduce its immunogenicity, thus making the transfected cells healthier and can express the target protein better.
Modifications help stabilize mRNA and reduce its immunogenicity.
We can substitute uridine bases with either 5-moU, N1-me-Ψ, Ψ, 5’-iodourdine, or Cy5-UTP.
We can substitute cytidine bases with 5-me-C, 5’-iodocytidine, or thiol-CTP.
We can substitute customizable percentage substitutions upon request. These will be not site specific modifications.
Capping can stablize RNA from 5'end and recruit ribosome. Cap1 and Cap 2 have a higher impact on mRNA stability compared to Cap 0 regarding protecting the mRNA from exonuclease degradation. It is common to use Cap1 for mammalian cells and Cap 0 for plant cells. Cap2 is a novel solution provided by GenScript that may work better than Cap1 in mammailan cells especiailly in immune-stressed conditions.
Cap1 via co-transcriptional capping is our default recommendation. We can also offer Cap0 and Cap1 enzymatically for an additional cost, and Cap2 RNA through co-transcriptional capping technology.
GenScript's proprietary capping technology can achieve >97% capping efficiency.
Yes, we offer mRNA QC service including capping efficiency assay using enzyme digestion /LC-MS method. Please contact our technical support team for details.
We use linearized DNA plasmid as a template for manufacturing your mRNA. The gene can be designed by our team using GenScript’s proprietary vectors and tools or we can use one of your designs. Once the design has been agreed to, we handle the gene and mRNA manufacture and provide you with mRNA as part of the fee-for-service agreement.
Yes, it is possible, please contact our technical support team.
For making cap1 mRNA using co-transcriptional capping technology, either AGG or GGG following T7 promoter seq is required. For self-amplifying RNA usually ATG after T7 promoter.
Yes, we can do codon optimization. Please contact our technical support team.
Yes. we can subclone your ORF sequences into our proprietary vector which contains T7 promoter, UTR and 100A for mRNA production.
We use RNaseT1.
Yes, please refer to https://www.genscript.com/mrna-qc-services.html.
Approximately 0.5ug to 1 ug of mRNA is usually used for transfecting each well in 24 well plate.